Quest for the right Drug

|
עמוד הבית / סימדקס 2.5 מ"ג/מ"ל / מידע מעלון לרופא

סימדקס 2.5 מ"ג/מ"ל SIMDAX 2.5 MG/ML (LEVOSIMENDAN)

תרופה במרשם תרופה בסל נרקוטיקה ציטוטוקסיקה

צורת מתן:

תוך-ורידי : I.V

צורת מינון:

תרכיז להכנת תמיסה לאינפוזיה : CONCENTRATE FOR SOLUTION FOR INFUSION

Adverse reactions : תופעות לוואי

4.8      Undesirable effects
In placebo-controlled clinical trials for ADHF (REVIVE programme), 53% of patients experienced adverse reactions, the most frequent of which were ventricular tachycardia, hypotension, and headache.

In a dobutamine-controlled clinical trial for ADHF (SURVIVE), 18% of patients experienced adverse reactions, the most frequent of which were ventricular tachycardia, atrial fibrillation, hypotension, ventricular extrasystoles, tachycardia, and headache.

The following table describes the adverse reactions observed in 1% or greater of patients during REVIVE I, REVIVE II, SURVIVE, LIDO, RUSSLAN, 300105, and 3001024 clinical trials. If the incidence of any particular event in an individual trial was greater than that seen across the other trials, then the higher incidence is reported in the table.

The events considered at least possibly related to levosimendan are displayed by system organ class and frequency, using the following convention: very common (≥ 1/10), common (≥ 1/100 < 1/10).
Table 3
Summary of Adverse Reactions
SURVIVE Clinical Study, REVIVE Programme, and
LIDO/RUSSLAN/300105/3001024 Clinical Studies combined
Body System                  Frequency         Preferred Term
Metabolism and nutrition     Common            Hypokalaemia disorders
Psychiatric disorders        Common            Insomnia
Nervous system disorders     Very Common       Headache
Common            Dizziness
Cardiac disorders            Very Common       Ventricular Tachycardia Common            Atrial Fibrillation
Tachycardia
Ventricular Extrasystoles
Cardiac Failure
Myocardial Ischaemia
Extrasystoles
Vascular disorders           Very Common       Hypotension
Gastrointestinal disorders   Common            Nausea
Constipation
Diarrhoea
Vomiting
Investigations               Common            Haemoglobin Decreased 
Post-marketing adverse reactions:
In post-marketing experience, ventricular fibrillation has been reported in patients being administered Simdax.
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Any suspected adverse events should be reported to the Ministry of Health according to the National Regulation by using an online form: https://sideeffects.health.gov.il 
שימוש לפי פנקס קופ''ח כללית 1994 לא צוין
תאריך הכללה מקורי בסל לא צוין
הגבלות לא צוין

בעל רישום

BIO-MED - J.R LTD, ISRAEL

רישום

129 66 30801 00

מחיר

0 ₪

מידע נוסף

עלון מידע לרופא

17.05.18 - עלון לרופא 20.04.22 - עלון לרופא

עלון מידע לצרכן

20.04.22 - החמרה לעלון

לתרופה במאגר משרד הבריאות

סימדקס 2.5 מ"ג/מ"ל

קישורים נוספים

RxList WebMD Drugs.com